If tolerability is acceptable, sandwich regimens could deliver both rapid tumor shrinkage and durable recurrence prevention, particularly when coupled with emerging biomarkers such as KIM-1, radiomics, and CD8+/CD39+ immune phenotypes. Here, ENTPD1 is linked to neoplasm.